Breed · Dog

Boxer: adverse event reports

FDA breed label "Boxer (German Boxer)" · single-breed animals only

Read this first · FDA's caveat, in its words

An API dataset query result cannot be used to estimate the risk associated with the product or compare one drug or device product with another. When looking at the results, be aware that there is no certainty that the reported drug or device caused the adverse event. This dataset should not be the sole source of information for clinical decision-making or other assumptions about the safety or effectiveness of a product. The adverse event may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources. FDA Center for Veterinary Medicine

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

Not veterinary advice. This site lists what was reported to FDA. For an animal that is unwell, contact a veterinarian.

18,925reports, 1987–20261.9% of dog reports

544reports, 12 months to March 2026681 in the 12 months before

39.1%classed serious, as reportedall dogs: 38.3%

19.4%name milbemycin oxime + spinosadall dogs: 13.1%

18,925 adverse event reports received by FDA describe an animal recorded as Boxer (FDA breed label "Boxer (German Boxer)"). That is 1.9% of all reports about dogs. Crossbred animals are not counted here, only reports that give this single breed.

544 reports arrived in the 12 months to March 2026, down 20% from 681 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are milbemycin oxime + spinosad, ivermectin + pyrantel pamoate and moxidectin. Milbemycin Oxime + Spinosad is named in 19.4% of this breed's reports, a larger share than in reports about all dogs (13.1%).

The terms listed most often are vomiting (21.1%), lethargy (11.2%) and emesis (9.6%). Vomiting appears in 21.1% of reports, about the same share as in all dog reports (19.7%). 39.1% of reports stating seriousness were classed as serious, against 38.3% for dogs overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drug	Reports	Share of Boxer reports	Share of all dog reports
Milbemycin Oxime + Spinosad	3,676	19.4%	13.1%
Ivermectin + Pyrantel Pamoate	2,522	13.3%	14.9%
Moxidectin	1,419	7.5%	5%
Spinosad	1,412	7.5%	5.8%
Fluralaner	944	5%	6.7%
Carprofen	752	4%	4.8%
Afoxolaner	689	3.6%	5.7%
Milbemycin Oxime	674	3.6%	3%
Melarsomine Dihydrochloride	638	3.4%	2.3%
Oclacitinib	604	3.2%	2.9%
Selamectin	555	2.9%	3%
Lufenuron + Milbemycin Oxime	514	2.7%	2.7%
Pyrantel Pamoate + Sarolaner	476	2.5%	5.1%
Milbemycin Oxime + Praziquantel	407	2.2%	3.1%
Bedinvetmab	308	1.6%	1.9%
Ivermectin	277	1.5%	1.3%
Deracoxib	271	1.4%	1.1%
Cyclosporine	267	1.4%	1.5%
Trilostane	263	1.4%	1.2%
Firocoxib	241	1.3%	0.8%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of Boxer reports listing the termall dog reports

Vomiting21.1%3,995
Lethargy[unusually tired or inactive]11.2%2,126
Emesis[vomiting]9.6%1,820
Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]9.3%1,760
Diarrhoea[diarrhea]6.1%1,162
Anorexia[not eating]5.2%984
Depression[dull, quiet or withdrawn]4.4%841
Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]4.3%820
Lack of efficacy - NOS[the product did not have the expected effect]4%765
Lack of efficacy (endoparasite) - heartworm[the product did not have the expected effect: heartworm]3.8%723
Seizure NOS[seizure, type not specified]3.5%656
Ataxia[unsteady, uncoordinated movement]3%559
Hives2.9%554
Death2.7%510
Anaphylaxis[sudden severe allergic-type reaction]2.7%506
Urticaria[hives]2.6%497
Death by euthanasia[the animal was euthanized]2.5%479
Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]2.5%474
Behavioural disorder NOS[behaviour change, type not specified]2.1%399
Weight loss2.1%395
Facial swelling2%384
Other abnormal test result NOS[abnormal laboratory result, type not specified]2%381
Not eating1.9%369
Digestive tract disorder NOS[digestive problem, type not specified]1.9%356
Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]1.7%328

Age and weight

Age of the animal

Under 1 year13%2,466

1 to 3 years36.2%6,858

4 to 7 years28.5%5,389

8 to 11 years17%3,220

12 years and over2.8%538

Age not given2.4%454

Weight of the animal

Under 5 kg (11 lb)0.9%177

5 to 9.9 kg (11–22 lb)2%376

10 to 24.9 kg (22–55 lb)26.7%5,056

25 to 44.9 kg (55–99 lb)65.2%12,348

45 kg and over (99 lb+)1.4%261

Weight not given3.7%707

Coloured bar: Boxer reports. Grey bar: all dog reports.

Trend and outcomes

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal28.2%5,345

Recovered with Sequela4%755

Ongoing16.3%3,076

Died3.8%722

Euthanized1.7%331

Outcome Unknown20.1%3,807

Beside all dogs

Measure	Boxer	All dogs
Reports	18,925	985,675
Latest 12 months	544	53,292
Classed serious, of reports stating it	39.1%	38.3%
Death or euthanasia recorded, per 1,000 reports	55.6	55

Questions about Boxer reports

How many FDA adverse event reports involve Boxers?

18,925 reports through March 2026, 1.9% of reports about dogs; 544 in the latest 12 months.

Which drugs are named most often in Boxer reports?

By active ingredient: milbemycin oxime + spinosad (3,676), ivermectin + pyrantel pamoate (2,522), moxidectin (1,419), spinosad (1,412) and fluralaner (944). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (21.1%), lethargy (11.2%), emesis (9.6%), ineffective, heartworm larvae (9.3%) and diarrhoea (6.1%).

Is the Boxer more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Boxer animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 30 Sep 2026. Breed names are FDA's labels rearranged into everyday order ("Boxer (German Boxer)" becomes "Boxer"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.